Discover Great Companies Discover Great Clients
Popularity  8.6万   |   Followers  94   |   Likes  10   |   Feedback  63 Claim this company

Let people share the health and happiness brought by technology

No.2 Kunming City Popularity Ranking No.1 Wuhua District No.2 Yunnan Pro No.1 Research Institute No.1 Sheng Ming Ke Xue No.1 Lin Chuang Yi Xue No.1 Public Health No.1 Ke Xue Yan Jiu No.1 Healthcare Technology No.1 Biotechnology Pharmaceuticals No.1 Xue Shu Yan Jiu No.2 Pharmaceutical Technology No.2 Yi Yao Jing Ji No.2 Biological Products No.2 Health 国家高新技术企业 理事单位 国家技术创新示范企业 高新技术企业 国家企业技术中心 科技领军企业
More

Company Overview

  • Nature: Listed Company Size: 1000-4999 employees Founded: 25年
  • Industry: Pharmaceutical/Bioengineering 、 Raw materials and processing 、 Academic/Scientific research
  • Full name: Yunnan Walvax Biotechnology Co., Ltd.。

Development Stage

  • Stage: IPO上市, 创业板, 深交所。
  • Ranking: Ranked #2 in Kunming City by popularity Ranked #1 in Kunming Research Institute Company by popularity Ranked #1 in Kunming Sheng Ming Ke Xue Company by popularity Ranked #1 in Kunming Lin Chuang Yi Xue Company by popularity Ranked #1 in Kunming Public Health Company by popularity
  • Honors: 2024中国新经济500强 2023中国企业慈善公益500强 国家高新技术企业 理事单位 According to algorithm
  • News: 2026-09-10:沃森生物:子公司新冠mRNA疫苗获批上市。
  • Salary: 41.8% of positions earn 6-10K, In 2026 vs last yeargrew by 11%.。Master's salary: ¥15.3K, Doctorate salary: ¥27.9K.
  • R&D: "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 29.4%, "Other (R&D and Technical)": 22.9%, "Scientific Research": 17.8%。
  • Recruiting: In 2026 vs 2025grew by 46%. Demand for highly educated talent: Master's: 46, Doctorate: 6.
  • Requirement: Education: 本科 leads with 55.6%. Experience: 不限 leads with 33.7%.
  • Region: Distributed across 7 regions, 昆明: 61.3%, 上海: 14.8%, 无锡: 7.1%, 玉溪: 5.2%.

About the Company

[Summary] Let people share the health and happiness brought by technology

Yunnan Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax Biotechnology" or "the Company"), established in 2001, is a high-tech biopharmaceutical enterprise specializing in human vaccines, integrating research and development, production, and sales. It holds a leading position in the segmented field of biotechnological drugs represented by novel vaccines. On November 12, 2010, the Company was listed on the Shenzhen Stock Exchange (stock code: 300142), becoming the first ChiNext-listed company in Yunnan.
The Company's headquarters is located in Kunming City, Yunnan Province, China. It is committed to the research and development of innovative vaccines, with R&D investment accounting for over 20% of revenue for many consecutive years, ranking among the top three in the industry. It has now established mature and stable bacterial vaccine technology platforms and recombinant protein vaccine technology platforms, and has gradually built mRNA vaccine technology platforms and recombinant adenovirus vaccine technology platforms through joint efforts with partners. Currently, the Company has obtained approval for marketing 8 vaccine varieties (14 specifications). In addition, a COVID-19 variant mRNA vaccine (Omicron XBB.1.5) was approved for emergency use in December 2023, making the Company the domestic enterprise with the most comparative advantages in the number of self-developed vaccine products and variety layout. As of December 31, 2025, the cumulative number of product batch releases has exceeded 360 million doses (bottles). The Company is the first in China and the second globally to independently develop and successfully market a 13-valent pneumococcal conjugate vaccine, which has maintained a leading market share in China since 2021. The Company is also the second in China and the fourth globally to independently develop and successfully market a bivalent HPV vaccine, which passed WHO PQ certification on August 2, 2024, marking another important milestone in the Company's international business expansion. Furthermore, the Company's COVID-19 variant mRNA vaccine (Omicron XBB.1.5) is also the first COVID-19 mRNA vaccine in China targeting current variants such as XBB, approved for emergency use based on complete Phase III safety and efficacy data through immunogenicity bridging clinical trials.
The Company actively seizes opportunities in national strategic emerging industries, comprehensively coordinates resource conditions, industrial factors, and capability advantages. In the field of biomanufacturing, it has laid out product pipelines including nutrients, active ingredients of natural products, and functional proteins, and is steadily advancing R&D and industrialization. Meanwhile, in the field of gut microbiota, the Company has begun implementing a dual-track layout of "disease treatment intervention" and "chronic disease prevention and treatment + comprehensive health nutrition," aiming to establish comprehensive health solutions covering in-hospital treatment, out-of-hospital management, and multi-scenario intervention. At present, this project has entered the implementation stage. The Company will fully leverage its existing R&D and industrialization capabilities and advantages, concentrate resources to promote project implementation, expand its business areas and product pipelines, strive to open up new business growth curves, and contribute to the Company's long-term sustainable development.
The Company has always adhered to the corporate mission of "Sowing Health, Creating Beauty," upholding the purpose of "Let everyone be born healthy," and is committed to creating innovative biotechnological products with excellent quality and good accessibility, becoming a leading and sustainable international vaccine manufacturer, contributing Walvax's strength to the development of Healthy China and global public health.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Walvax Biotechnology Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 创业板
  • Deal: 深交所

Walvax Biotechnology How Fast Is Hiring Growing? (146 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 138%
  • 2024: Down 16%
  • 2023: Up 142%
  • 2022: Down 75%
Walvax Biotechnology Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Walvax Biotechnology Campus Recruitment & Advanced Degree Talent Demand
Interns 1 Master's 46 Doctorate 6
Note: How fast is hiring at Yunnan Walvax Biotechnology Co., Ltd. growing? Walvax Biotechnology2026: 373 openings (up 46%), 2025: 255 openings (up 138%), 2024: 107 openings (down 16%), 2023: 128 openings (up 142%), 2022: 53 openings (down 75%), 2021: 213 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Walvax Biotechnology Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 138%
  • 2024: Down 10%
  • 2023: Up 123%
  • 2022: Up 18%
Walvax Biotechnology Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Yunnan Walvax Biotechnology Co., Ltd. growing? Walvax BiotechnologyMaster's recruitment over the years: 2025: 62 openings (up 138%), 2024: 26 openings (down 10%), 2023: 29 openings (up 123%), 2022: 13 openings (up 18%), 2021: 11 openings. Walvax Biotechnology master talent ranking in Kunming: #2, Walvax Biotechnology master salary mostly around 8-15K.

Walvax Biotechnology Doctoral Degree Job Demand Analysis

(More)
+188%
Growth Rate
2026 vs 2025
Walvax Biotechnology Doctoral Hiring by Year: 2026 — 15 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Yunnan Walvax Biotechnology Co., Ltd. growing? Walvax BiotechnologyDoctorate recruitment over the years: 2026: 23 openings (up 76%), 2025: 8 openings (up 138%). Walvax Biotechnology doctorate talent ranking in Kunming: #4, Walvax Biotechnology doctorate salary mostly around 20-50K.

Walvax Biotechnology R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Yunnan Walvax Biotechnology Co., Ltd.? Based on an analysis of Walvax Biotechnology's job postings over the past year, "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 29.4%, "Other (R&D and Technical)": 22.9%, "Scientific Research": 17.8%, "Medical & Health/Beauty & Healthcare": 9.3%, "Computer/Network/Technology": 6.5%, "Agriculture, Forestry and Fishery": 2.5%. For reference only.

Walvax Biotechnology — What Are the Salaries Like? (431 records)

Manage
salary range: 4.5K - 50K, 41.8% of roles pay ¥6-10K
Note: salary statistics are based on 431 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Yunnan Walvax Biotechnology Co., Ltd.?Walvax Biotechnology41.8% of positions earn 6-10K, Fresh graduate salary: ¥2.5K。Kunming salary ranking top 10,生物/制药/化工/环保类 average salary ¥15.0K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Walvax Biotechnology

(More)
Are salaries high at Yunnan Walvax Biotechnology Co., Ltd.? We provide: Researcher, Management Specialist, Senior Specialist, Quality, Marketing, Sales, Brand, Project Management, Provincial Manager, Operations, Intern, Legal Counsel, Analyst, 平台负责人, 临床, QC, Product Development Specialist, Information, 制剂研究, Business Development. Click to view detailed salary analysis by job.

Walvax Biotechnology — Fortune 500? (More)

Yes, ranked in 中国新经济500强:

  • NO.346 2024中国新经济500强 >
  • NO.168 2023中国新经济500强 >
  • NO.97 2022中国新经济500强 >

Yes, ranked in 中国企业慈善公益500强:

  • NO.281 2023中国企业慈善公益500强 >
  • NO.422 2022中国企业慈善公益500强 >

Walvax Biotechnology honors, qualifications & industry associations

Job Category

  • 生物/制药/化工/环保类
    28.9% of total 28.9%
  • 经营管理类
    27.8% of total 27.8%
  • 其他(研发和技术类)
    22.3% of total 22.3%
  • 科研类
    17.3% of total 17.3%

Education

  • 本科
    55.6% of total 55.6%
  • 硕士
    29.4% of total 29.4%
  • 大专
    6.2% of total 6.2%
  • 博士
    6.2% of total 6.2%

Experience

  • 不限
    33.7% of total 33.7%
  • 3-5年
    26.2% of total 26.2%
  • 1-3年
    26.2% of total 26.2%
  • 5-10年
    13.4% of total 13.4%
View Detailed Analysis

What does Yunnan Walvax Biotechnology Co., Ltd. require? Who is Walvax Biotechnology hiring? Walvax Biotechnology recruitment: 生物/制药/化工/环保类占比最多占28.9%,其次是经营管理类占27.8%. What education can get in at Walvax Biotechnology? 本科占比最多占55.6%,其次是硕士占29.4%. High education required at Walvax Biotechnology? 硕士占29.4%,博士占6.2%. Work experience required at Walvax Biotechnology? 不限占比最多占33.7%,其次是3-5年占26.2%. Where are the job locations at Walvax Biotechnology? 昆明占比最多占61.3%,其次是上海占14.8%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 159,934.8541万(元)
Legal Representative: 李云春
Date Established:
Credit Code: 91530000719480244Y
Registered Address: 云南省昆明市高新区科新路395号

Partners & Suppliers

提供疫苗生产设备 Source
供应商 制药企业客户
公司为其疫苗研发及生产提供细胞培养基及CDMO服务 Source
供应商 疫苗
提供mRNA疫苗生产所需原料酶及试剂 Source
供应商 mRNA原料酶及试剂
为沃森生物mRNA新冠疫苗提供培养基 Source
供应商 疫苗
国控云南为沃森生物疫苗在云南区域的配送商,采购其生物制品。 Source
合作客户 生物制品供应商

People who follow Walvax Biotechnology also follow

Walvax Biotechnology Competitors (Similar Companies)

“An important representative of traditional Chinese medicine and a busi”
“Building China's skin health ecosystem and promoting the development o”
“Help farmers raise good pigs, let consumers eat good meat”
“Comprehensive fertilizer manufacturer”
“Green KPC, Benefits Society”
工程咨询 工程设计 工程勘察 市政工程
“疫苗生产商”
制药/药业 医药 生物科技/生物工程 医药工业
流程自动化 软件 翻译 特殊教育
“让家居更适宜”
报检 报关报检 报关 仓储
“一家专业从事磷化工产业的民营股份制企业”
“Providing first-class solutions for global new energy applications”
“Committed to using technology to make life better in a world where hum”
“Retail pharmacy chain”

Discover Great Companies, Discover Great Clients

昆明公司名录 昆明“Wuhua District”公司名录 昆明“生物科技/生物工程”公司名录 昆明“医药”公司名录 昆明“生物制药”公司名录 昆明“制药/药业”公司名录 昆明“药物研发”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates